The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|December 15, 2016
Metastatic Non-Small Cell Lung Cancer with Alexander Drilon, MD: Case 1
Metastatic Non-Small Cell Lung Cancer with Alexander Drilon, MD
Advertisement
Casee Scenario 1:
Robert P is a 72 year old retired factory worker from Detroit, Michigan.His medical history is notable for hypertension (well-controlled), hyperuricemia, and gout.
In September of 2015, he presents to his PCP with fatigue, progressive dyspnea, and a persistent, nonproductive cough of approximately 1 month’s duration. He is a former smoker and quit approximately 30 years ago.
- Chest X-ray in October 2015 showed a large mass in the upper left lobe and CT scan showed a left malignant pleural effusion and enlargement of the right mediastinal and hilar lymph nodes.
- MRI of the brain was negative for intracranial metastases.
- The patient underwent resection of the primary mass and biopsy of the affected lymph nodes which showed large cell carcinoma.
- His lung cancer was staged as 4; Biopsy of the primary lesion and lymph node metastases were sent for molecular testing and showed no actionable mutations in EGFR or ALK.
- His current performance status is 0.
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5